Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
May 30 2023 - 8:30AM
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
(Nasdaq: LIXT) today announced that a recently published article in
the journal Cancer Research showed that PP2A, the pharmacologic
target of LIXTE’s lead clinical compound, LB-100, when inactivated
in pre-clinical models of glioma, activates a complex intracellular
signaling system, the cGAS-STING pathway. This leads to an
activation of interferon signaling, an increase in MHC class I
expression on tumor cells, an increase in CD8+ killer T cell
proliferation, while at the same time reducing immunosuppressive
tumor associated macrophages. Consequently, as shown in the
article, PP2A inactivation sensitized the immunologically “cold”
glioblastoma cells to immune checkpoint blockade therapy in vivo.
The May 23, 2023 article in the journal Cancer
Research, entitled “PP2Ac Deficiency Enhances Tumor Immunogenicity
by Activating STING-Type I Interferon Signaling in Glioblastoma,”
by Mondal et al. from the Department of Neurological Surgery,
University of California, San Francisco.
John S. Kovach, M.D., CEO and Founder of LIXTE,
said, “The case for combining LB-100 with immunotherapy is ever
more compelling. We reported last year on emerging clinical
evidence that PP2A inhibition may sensitize clear cell ovarian
cancer patients to checkpoint inhibitors
(https://ir.lixte.com/news-events/press-releases/detail/77/inactivating-mutations-in-scaffold-component-of-pp2a-the).
We currently have one active multi-center trial in which LB-100 is
combined with immunotherapy and chemotherapy in small cell lung
cancer (NCT04560972), and are finalizing additional trials of
LB-100 with immunotherapy for treatment of immunologically
unresponsive tumors.”
Dr. Kovach continued, “Lixte has long been
interested in determining whether LB-100 potentiates standard
treatment of glioblastomas. Thanks to the work of Mondal et al., we
are now keenly interested in assessing whether LB-100 facilitates
immunotherapy of primary brain tumors, among other immunologically
‘cold’ tumors for which more effective treatments are needed.”
Rene Bernards, Professor of Molecular
Carcinogenesis at the Netherlands Cancer Institute and member of
the LIXTE Board of Directors, commented, “Our own recent research
provides yet another reason to combine LB-100 with immunotherapy as
phospho-proteomic analysis of LB-100 treated colon cancer cells
identifies mRNA processing as a major pathway perturbed by LB-100.
As a consequence of LB-100 exposure, colon cancer cells contain a
significant amount of incorrectly spliced mRNAs, which is a known
source of neo-antigens that can help turn an immunologically ‘cold’
tumors ‘hot’ and vulnerable to immunotherapy.”
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a
clinical-stage pharmaceutical company focused on new targets for
cancer drug development and on developing and commercializing
cancer therapies. LIXTE has achieved a breakthrough demonstrating
that its first-in-class lead clinical PP2A inhibitor, LB-100, is
well-tolerated in cancer patients at doses associated with
anti-cancer activity. Based on extensive published preclinical data
(see www.lixte.com), LB-100 has the potential to significantly
improve outcomes for patients undergoing various chemotherapies or
immunotherapies. LIXTE's new approach has no known competitors and
is covered by a comprehensive patent portfolio. Initial
proof-of-concept clinical trials are in progress.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future activities, including the continuing development of
proprietary compounds, the planning, funding, coordination and
potential results of clinical trials, and the patent and legal
costs to protect and maintain the Company's intellectual property
worldwide, are all forward-looking statements. These statements are
generally accompanied by words such as "intend," anticipate,"
"believe," "estimate," "potential(ly)," "continue," "forecast,"
"predict," "plan," "may," "will," "could," "would," "should,"
"expect" or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at https://www.sec.gov.
For more information about
LIXTE, Contact:
info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888)
289-5533
or
PondelWilkinson Inc. Investor
Relationspwinvestor@pondel.comRoger Pondel: (310) 279-5965Laurie
Berman: (310) 279-5962
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lixte Biotechnology (NASDAQ:LIXT)
Historical Stock Chart
From Sep 2023 to Sep 2024